Impacto del tratamiento con irbesartán sobre la reducción del riesgo cardiovascular de pacientes hipertensos en España. Estudio KORAL-HTA

BP and MAU decrease with Irbesartan treatment is associated to a decrease in GCR in hypertensive patients. This study also confirms under clinical practice conditions that the benefits on MAU are not only limited to patients with DM but also to the non-diabetics and are constant in the different BMI ranges.